Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 18;7(2):225–232. doi: 10.1002/jcsm.12054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the Creative Commons Attribution‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

PMC Copyright notice

Anti‐cachexia efficacy of salidroside in the combined chemotherapy in CT‐26 models. Here, cachexia model induced by CT‐26 was established again, and further study of combined chemotherapy was performed to focus evaluations of anti‐cachexia efficacy of salidroside. Tumour‐bearing mice were treated with NS, DDP (3 mg/kg/4 days), salidroside (120 mg/kg/day), and combination of salidroside (120 mg/kg/day) and single dose of DDP (3 mg/kg/4 days), respectively. Effects of salidroside on the main features of cachexia were examined, including (B) tumour growth, (C) body weight, (D) tumour‐free body weight, (E) gastrocnemius muscle, (A) fat mass (bottom, epididymal WAT; top panel, gonadal WAT), and (F) survival. Results are expressed as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). WAT, white adipose tissue; NS, the control group; DDP, cisplatin.